Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The costs for atrial fibrillation (AF) hospitalisations were significantly lower in the amiodarone group. Cardioversions were significantly less frequent in the amiodarone group. There was no statistically significant difference in the total hospital cost, or the combined hospital and physician costs. The authors believed that this was most likely related to health problems unrelated to AF or amiodarone.